Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types Colorectal cancer affects over 150,000 new patients in the U.S. annually, with many patients ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care ...

Tempus AI Inc. (NASDAQ:TEM) is one of the best young stocks to buy and hold for 5 years. On July 8, Tempus AI announced the expansion of its care pathway intelligence platform, called Tempus Next, to ...

Tempus AI is rated a strong buy for risk-tolerant investors, leveraging its vast proprietary healthcare data to drive ...

Tempus will now offer the ArteraAI Prostate Test to cancer centers across the U.S. Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and ...

Up to 50% of patients with ER+/HER2- mBC could develop ESR1 mutations as a result of prior exposure to endocrine therapy in the metastatic setting. Testing to identify these mutations can help ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a ...

Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines. “Staying current with rapidly evolving clinical guidelines—especially regarding biomarker ...

Tempus AI TEM has recently expanded its AI-enabled care pathway intelligence platform, Tempus Next, into breast cancer to address critical care gaps in breast cancer care. Initially designed for lung ...

Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance ...